# AVITA Medical to Present at the 44th Annual J.P. Morgan Healthcare Conference
Canonical URL: https://biopharmsignal.com/news/RCEL/avita-medical-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-7f45670e
Ticker: RCEL
Company: Avita Medical
Source: Avita Medical
Published: 2025-12-18 21:15 EST
## Summary

Acute wound care company AVITA Medical will present at the 2026 annual J.P. Morgan healthcare conference...

## Article Body
AVITA Medical ® , Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that Cary Vance, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026, at 5:15 p.m. Pacific Time.

A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's website at https://ir.avitamedical.com/events-and-presentations. A replay of the webcast will be available following the conclusion of the event.

About AVITA Medical, Inc.

AVITA Medical ® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is the RECELL ® System, approved by the U.S. Food and Drug Administration for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™ Cells, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the rights to manufacture and exclusive rights to market, sell, and distribute PermeaDerm ® , a biosynthetic wound matrix, and the exclusive rights to market, sell, and distribute Cohealyx™, an AVITA Medical-branded collagen-based dermal matrix.

In international markets, the RECELL System is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds, with regulatory clearances in Europe, and excluding RECELL GO, in Australia and Japan.

To learn more, visit www.avitamedical.com.

Investor & Media Contact: Ben Atkins Phone +1-805 341 1571 investor@avitamedical.com | media@avitamedical.com

Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
## Recent Company News
- 2026-07-14 20:05 EST — [AVITA Medical to Announce Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RCEL/avita-medical-to-announce-second-quarter-2026-financial-results-8e67c186) — Source: Avita Medical
- 2026-06-18 12:40 EST — [AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting](https://biopharmsignal.com/news/RCEL/avita-medical-highlights-first-u-k-clinical-experience-with-recell-go-at-british-188835be) — Source: Avita Medical
- 2026-05-17 22:00 EST — [AVITA Medical to Host Investor Webinar Briefing](https://biopharmsignal.com/news/RCEL/avita-medical-to-host-investor-webinar-briefing-fc878ee8) — Source: Avita Medical
- 2026-05-14 20:05 EST — [AVITA Medical Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/RCEL/avita-medical-reports-first-quarter-2026-financial-results-fc8fc795) — Source: Avita Medical
- 2026-04-30 12:50 EST — [AVITA Medical Names Cary Vance as Chief Executive Officer](https://biopharmsignal.com/news/RCEL/avita-medical-names-cary-vance-as-chief-executive-officer-9d7f5bda) — Source: Avita Medical
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)